The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Market Overview

• 2023 Market Size:$7.05 billion
• 2024 Projected Market Size:$7.63 billion
• CAGR (2023-2024):2%

The drug-eluting stent market has experienced strong growth due to the need for improved treatment options, advancements in clinical evidence, regulatory approvals, and healthcare economics. This trend is expected to continue as new technologies and patient-centered approaches emerge.

Future Market Growth

• 2028 Projected Market Size:$10.52 billion
• CAGR (2024-2028):4%

Growth in the market is anticipated to be driven by an aging population, increasing chronic disease burden, expanding indications for use, favorable healthcare reimbursement policies, and the push towards patient-centered care. Key trends include personalized medicine, minimally invasive techniques, and next-generation drug formulations.

View More On The Drug Eluting Stent Market Report 2024 –
https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

Key Trends and Drivers

• Impact of Coronary Heart Disease:The rising prevalence of coronary heart disease (CHD) is a significant driver for the drug-eluting stent market. CHD, characterized by the narrowing or blockage of coronary arteries due to plaque buildup, can lead to severe complications such as heart attacks. Drug-eluting stents help address this issue by releasing medication that prevents re-narrowing of arteries. For instance, data from the Centers for Disease Control and Prevention (CDC) indicated an increase in the prevalence of CHD among adults from 4.6% in 2020 to 4.9% in 2022.
• Innovation in Stent Design:Companies are focusing on advancing drug-eluting stent technologies. For example, Medtronic’s Onyx Frontier, launched in August 2022, features a dual-layer balloon that improves drug delivery precision and stent deployment. This new generation of stents shows a 16% increase in deliverability compared to previous models.
• Personalized Medicine and Minimally Invasive Techniques:The shift towards personalized medicine and minimally invasive techniques is enhancing treatment efficacy and patient outcomes. These advancements are leading to more precise and effective interventions.
• Emerging Healthcare Technologies:Next-generation drug formulations and innovative delivery systems are pushing the boundaries of interventional cardiology, providing more effective solutions for coronary artery disease.

Strategic Acquisitions

• Cordis and MedAlliance:In October 2023, Cordis acquired MedAlliance, a move aimed at expanding its product portfolio in the coronary and peripheral vascular markets. MedAlliance’s expertise in drug-eluting stents aligns with Cordis’ goals to advance cardiovascular innovation.

Market Segmentation

• By Product: Polymer-Based, Polymer-Free
• By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs
• By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds
• By Application: Coronary Diseases, Peripheral Vascular Diseases
• By End-User: Hospitals, Specialty Clinics

Regional Insights

• North America:The largest market region in 2023, driven by advanced healthcare infrastructure and high adoption rates of new technologies.
• Asia-Pacific:Expected to be the fastest-growing region, fueled by increasing healthcare investments, rising prevalence of cardiovascular diseases, and expanding access to advanced medical technologies.

Conclusion

The drug-eluting stent market is set for continued strong growth, driven by advancements in technology, increasing prevalence of coronary heart disease, and a shift towards personalized and minimally invasive treatments. Innovations in stent design and strategic acquisitions are shaping the future landscape of this market.

Request A Sample Of The Global Drug Eluting Stent Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=15557&type=smp